Drug news
NICE draft guidance recommends therapies for Prevention of Breast Cancer
NICE (The National Institute of Health and Clinical Excellence) has produced draft guidance on familial Breast Cancer, proposing the use, over five years, of hormonal therapies, tamoxifen or Evista (raloxifene), by post menopausal women at a high risk of Breast Cancer. Both drugs reduce the risk but they do come with side effects, and these carry a different weight when being considered in a preventative strategy. Neither drug is indicated in the EU for prevention of Breast Cancer
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.